By Carlo Martuscelli 
 

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration had awarded its cancer drug Imfinzi orphan drug status as a treatment for small-cell lung cancer.

The designation is given to medicines that aim to treat rare diseases and provides benefits such as market exclusivity and faster regulatory approvals.

Imfinzi is currently approved as a treatment for inoperable stage 3 non-small-cell lung cancer after chemotherapy and radiation therapy.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

July 12, 2019 02:31 ET (06:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Astrazeneca Charts.